At what prices were the IRADIMED (IRMD) shares sold by the CEO-related trust?

The reported sales were executed at weighted average prices between $91.84 and $94.55 per share . Several trades occurred within narrower ranges, with detailed price intervals for each transaction day described in the accompanying footnotes.

How many IRADIMED (IRMD) shares does the CEO-related Phillip Susi 2008 Dynasty Trust hold after the sales?

After the April 14, 2026 transactions, the Phillip Susi 2008 Dynasty Trust held 2,210,000 shares of IRADIMED common stock indirectly. This figure is reported as the total shares beneficially owned by that trust following the sales.

Rule 10b5-1 sales by IRADIMED (IRMD) CEO-linked dynasty trust

Q: Who actually sold the IRADIMED (IRMD) shares reported for Roger E. Susi?

The sales were made by the Phillip Susi 2008 Dynasty Trust , an entity associated with Roger E. Susi. The filing notes he disclaims beneficial ownership of these securities except to the extent of his pecuniary interest in the trust.

Q: Were the IRADIMED (IRMD) insider sales made under a Rule 10b5-1 plan?

Yes. A footnote states the sales were effected under a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025 . Such plans pre-schedule trades, making the timing more routine and less discretionary.

Q: What other IRADIMED (IRMD) indirect holdings are reported for Roger E. Susi in this Form 4?

Beyond the dynasty trust, the filing lists 162,950 shares held by the Roger E. Susi Revocable Trust and 2,062,500 shares held by the Matthew Susi 2008 Dynasty Trust , both reported as indirect holdings as of April 13, 2026.

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

IRADIMED CORP director and CEO Roger E. Susi reported indirect open-market sales of 7,500 shares of common stock on April 13–14, 2026. The transactions were executed by the Phillip Susi 2008 Dynasty Trust at weighted average prices around $92–$94 per share under a Rule 10b5-1 trading plan adopted on November 5, 2025. Following these sales, the Phillip Susi 2008 Dynasty Trust held 2,210,000 shares indirectly, while separate indirect holdings reported include 162,950 shares held by the Roger E. Susi Revocable Trust and 2,062,500 shares held by the Matthew Susi 2008 Dynasty Trust as of April 13, 2026.

Insider Trade Summary 10b5-1

Net Seller: 7,500 shares ($697,189)

Net Sell 7 txns

Insider Susi Roger E.

Role CEO, President, Chairman

Sold 7,500 shs ($697K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,107	$93.71	$197K
Sale	Common Stock	393	$94.55	$37K
Sale	Common Stock	1,847	$91.84	$170K
Sale	Common Stock	2,564	$92.79	$238K
Sale	Common Stock	589	$93.45	$55K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 2,210,393 shares (Indirect, By Phillip Susi 2008 Dynasty Trust)

Footnotes (1)

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025. This transaction was executed in multiple trades at prices ranging from $91.28 to $92.22. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $92.35 to $93.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $93.29 to $94.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $93.17 to $94.13. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $94.24 to $94.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

Key Figures

Shares sold: 7,500 shares Sale price (low): $91.84 per share Sale price (high): $94.55 per share +4 more

7 metrics

Shares sold 7,500 shares Net open-market sales on April 13–14, 2026

Sale price (low) $91.84 per share Weighted average sale price on April 13, 2026

Sale price (high) $94.55 per share Weighted average sale price on April 14, 2026

Phillip Susi 2008 Dynasty Trust holdings 2,210,000 shares Indirect common stock after April 14, 2026 sales

Roger E. Susi Revocable Trust holdings 162,950 shares Indirect common stock as of April 13, 2026

Matthew Susi 2008 Dynasty Trust holdings 2,062,500 shares Indirect common stock as of April 13, 2026

Rule 10b5-1 plan adoption date November 5, 2025 Plan governing the April 2026 share sales

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, Section 16, beneficial ownership, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported above reflects the weighted average sale price"

Section 16 regulatory

"shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose"

Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.

beneficial ownership financial

"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

04/15/2026 - 02:37 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Susi Roger E.

(Last)

(First)

(Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO

FLORIDA

32826

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, President, Chairman

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/13/2026		S⁽¹⁾		1,847	D	$91.84⁽²⁾	2,215,653	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	04/13/2026		S⁽¹⁾		2,564	D	$92.79⁽³⁾	2,213,089	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	04/13/2026		S⁽¹⁾		589	D	$93.45⁽⁴⁾	2,212,500	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	04/14/2026		S⁽¹⁾		2,107	D	$93.71⁽⁵⁾	2,210,393	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	04/14/2026		S⁽¹⁾		393	D	$94.55⁽⁶⁾	2,210,000	I	By Phillip Susi 2008 Dynasty Trust
Common Stock								162,950	I	By Roger E. Susi Revocable Trust
Common Stock								2,062,500⁽⁷⁾	I	By Matthew Susi 2008 Dynasty Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025.

2. This transaction was executed in multiple trades at prices ranging from $91.28 to $92.22. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $92.35 to $93.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $93.29 to $94.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $93.17 to $94.13. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $94.24 to $94.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

	/s/ Roger E. Susi	04/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

How many IRADIMED (IRMD) shares were sold in this Form 4 filing?

The filing shows that entities associated with CEO Roger E. Susi sold 7,500 shares of IRADIMED common stock. These were indirect, open-market sales executed by the Phillip Susi 2008 Dynasty Trust across multiple trades on April 13–14, 2026.

Who actually sold the IRADIMED (IRMD) shares reported for Roger E. Susi?

The sales were made by the Phillip Susi 2008 Dynasty Trust, an entity associated with Roger E. Susi. The filing notes he disclaims beneficial ownership of these securities except to the extent of his pecuniary interest in the trust.

Were the IRADIMED (IRMD) insider sales made under a Rule 10b5-1 plan?

Yes. A footnote states the sales were effected under a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025. Such plans pre-schedule trades, making the timing more routine and less discretionary.

What other IRADIMED (IRMD) indirect holdings are reported for Roger E. Susi in this Form 4?

Beyond the dynasty trust, the filing lists 162,950 shares held by the Roger E. Susi Revocable Trust and 2,062,500 shares held by the Matthew Susi 2008 Dynasty Trust, both reported as indirect holdings as of April 13, 2026.